Lack of significant effect of therapeutic propranolol on measurable platelet function in healthy subjects.
Propranolol, a non-selective beta blocker, was administered orally in therapeutic doses. The effects of a single dose (160 mg) and one week's treatment (80 mg twice a day) on platelet function were compared in healthy young subjects. There were no significant changes in circulating platelet aggregates, template bleeding time, platelet factor 3 availability and thromboxane beta 2 (TX beta 2) generation. Platelet aggregation responses as assessed by angle of slope and maximal percentage aggregation (all agonists) and lag phase (collagen) showed no changes of biological importance, although minor changes reaching significance were observed with some agonists. These findings suggest that propranolol does not significantly affect platelet function when taken at doses commonly encountered in clinical practice.
Department of Haematology, Derriford Hospital, Plymouth.
D H
DH
Pamphilon
R J
RJ
Boon
A G
AG
Prentice
A
A
Rozkovec
D000293:Adolescent; D000328:Adult; D001760:Bleeding Time; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D010977:Platelet Factor 3 / Q000032:analysis; D011433:Propranolol / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000096:biosynthesis
D010977:Platelet Factor 3; D013929:Thromboxane B2; D011433:Propranolol